KALA BIO Inc. (KALA)
KALA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.2600
-7.14% on the day
Market cap
$5.0M
Nano cap
Revenue · 2025
$0
No prior year to compare
Net income · 2025
-$27.0M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1479419/000110465926043782/0001104659-26-043782-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KALA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001479419 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$27.0M |
| Operating income | -$39.2M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.6M |
| Total assets | $9.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-22 |
| Latest annual report | 10-K | 2026-04-15 |
| Latest quarterly / interim | 10-Q | 2026-08-19 |
| Latest current report | 8-K | 2026-09-10 |
| Latest proxy | DEF 14A | 2026-09-24 |
Source: SEC EDGAR submissions feed, 673 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PULM | Pulmatrix Inc. | $1.38 | -3.50% | $5.0M |
| PCSA | Processa Pharmaceuticals Inc. | $1.77 | -6.84% | $5.0M |
| ADXN | Addex Therapeutics Ltd | $3.01 | -0.99% | $5.1M |
| XBIO | Xenetic Biosciences Inc. | $2.10 | -0.94% | $4.9M |
| GELS | Gelteq Limited | $0.4801 | -2.06% | $5.1M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.98 | +3.12% | $4.9M |
| SCNX | Scienture Holdings Inc. | $3.24 | -17.14% | $5.3M |
| LNAI | Lunai Bioworks Inc. | $1.03 | -7.21% | $4.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier